Therapeutic area intelligence for Bipolar Disorder with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 0
Companies: 2

Companies

AbbVie →

Bristol Myers Squibb →

Assets

ABBV-932 →

Bristol-Myers →

lamotrigine →

Recent signals(4)

ClinicalAugust 5, 2026

KarXT Study for Bipolar-I Disorder Mania Shows Potential Efficacy

A study is underway to assess the efficacy and safety of adjunctive KarXT in treating mania in Bipolar-I Disorder patients.

ClinicalJuly 4, 2026

Study on rTMS for Mood Shifts in Bipolar Disorder Underway

A new study is investigating the efficacy of rTMS in treating depression in bipolar disorder by targeting individualized brain regions.

ClinicalJune 29, 2026

Bristol-Myers Squibb Evaluates KarXT for Bipolar-I Disorder Manic Episodes

A clinical trial is underway to assess the efficacy and safety of KarXT in treating manic episodes of Bipolar-I Disorder.

ClinicalJune 19, 2026

AbbVie Initiates Trial for ABBV-932 in Bipolar Disorder Depressive Episodes

AbbVie is conducting a trial to evaluate the safety and efficacy of ABBV-932 in adults with depressive episodes linked to bipolar I or II disorder.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Bipolar Disorder →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.